Literature DB >> 17065593

Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study.

P Edison1, H A Archer, R Hinz, A Hammers, N Pavese, Y F Tai, G Hotton, D Cutler, N Fox, A Kennedy, M Rossor, D J Brooks.   

Abstract

OBJECTIVE: To investigate the association between brain amyloid load in Alzheimer disease (AD) measured by [11C]PIB-PET, regional cerebral glucose metabolism (rCMRGlc) measured by [18F]FDG-PET, and cognition.
METHODS: Nineteen subjects with AD and 14 controls had [11C]PIB-PET and underwent a battery of psychometric tests. Twelve of those subjects with AD and eight controls had [18F]FDG-PET. Parametric images of [11C]PIB binding and rCMRGlc were interrogated with a region-of-interest atlas and statistical parametric mapping. [11C]PIB binding and rCMRGlc were correlated with scores on psychometric tests.
RESULTS: AD subjects showed twofold increases in mean [11C]PIB binding in cingulate, frontal, temporal, parietal, and occipital cortical areas. Higher cortical amyloid load correlated with lower scores on facial and word recognition tests. Two patients fulfilling the clinical criteria for AD had normal [11C]PIB at baseline. Over 20 months this remained normal in one but increased in the cingulate of the other. Mean levels of temporal and parietal rCMRGlc were reduced by 20% in AD and these correlated with mini mental scores, immediate recall, and recognition memory test for words. Higher [11C]PIB uptake correlated with lower rCMRGlc in temporal and parietal cortices.
CONCLUSION: [11C]PIB-PET detected an increased amyloid plaque load in 89% of patients with clinically probable Alzheimer disease (AD). The high frontal amyloid load detected by [11C]PIB-PET in AD in the face of spared glucose metabolism is of interest and suggests that amyloid plaque formation may not be directly responsible for neuronal dysfunction in this disorder.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17065593     DOI: 10.1212/01.wnl.0000244749.20056.d4

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  195 in total

1.  The dynamics of Alzheimer's disease biomarkers in the Alzheimer's Disease Neuroimaging Initiative cohort.

Authors:  A Caroli; G B Frisoni
Journal:  Neurobiol Aging       Date:  2010-06-11       Impact factor: 4.673

2.  Increased regional cerebral glucose uptake in an APP/PS1 model of Alzheimer's disease.

Authors:  Géraldine Poisnel; Anne-Sophie Hérard; Nadine El Tannir El Tayara; Emmanuel Bourrin; Andreas Volk; Frank Kober; Benoit Delatour; Thierry Delzescaux; Thomas Debeir; Thomas Rooney; Jésus Benavides; Philippe Hantraye; Marc Dhenain
Journal:  Neurobiol Aging       Date:  2011-11-12       Impact factor: 4.673

Review 3.  Amyloid imaging as a biomarker for cerebral β-amyloidosis and risk prediction for Alzheimer dementia.

Authors:  William E Klunk
Journal:  Neurobiol Aging       Date:  2011-12       Impact factor: 4.673

4.  Amyloid and metabolic positron emission tomography imaging of cognitively normal adults with Alzheimer's parents.

Authors:  Lisa Mosconi; Juha O Rinne; Wai H Tsui; John Murray; Yi Li; Lidia Glodzik; Pauline McHugh; Schantel Williams; Megan Cummings; Elizabeth Pirraglia; Stanley J Goldsmith; Shankar Vallabhajosula; Noora Scheinin; Tapio Viljanen; Kjell Någren; Mony J de Leon
Journal:  Neurobiol Aging       Date:  2012-04-11       Impact factor: 4.673

Review 5.  Molecular brain imaging in the multimodality era.

Authors:  Julie C Price
Journal:  J Cereb Blood Flow Metab       Date:  2012-03-21       Impact factor: 6.200

6.  Pittsburgh compound B (11C-PIB) and fluorodeoxyglucose (18 F-FDG) PET in patients with Alzheimer disease, mild cognitive impairment, and healthy controls.

Authors:  D P Devanand; Arthur Mikhno; Gregory H Pelton; Katrina Cuasay; Gnanavalli Pradhaban; J S Dileep Kumar; Neil Upton; Robert Lai; Roger N Gunn; V Libri; Xinhua Liu; Ronald van Heertum; J John Mann; Ramin V Parsey
Journal:  J Geriatr Psychiatry Neurol       Date:  2010-04-29       Impact factor: 2.680

Review 7.  Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives.

Authors:  Harald Hampel; Richard Frank; Karl Broich; Stefan J Teipel; Russell G Katz; John Hardy; Karl Herholz; Arun L W Bokde; Frank Jessen; Yvonne C Hoessler; Wendy R Sanhai; Henrik Zetterberg; Janet Woodcock; Kaj Blennow
Journal:  Nat Rev Drug Discov       Date:  2010-07       Impact factor: 84.694

8.  Long-Term Cognitive Improvement After Benfotiamine Administration in Patients with Alzheimer's Disease.

Authors:  Xiaoli Pan; Zhichun Chen; Guoqiang Fei; Shumei Pan; Weiqi Bao; Shuhua Ren; Yihui Guan; Chunjiu Zhong
Journal:  Neurosci Bull       Date:  2016-10-01       Impact factor: 5.203

Review 9.  Amyloid Imaging: Poised for Integration into Medical Practice.

Authors:  Keshav Anand; Marwan Sabbagh
Journal:  Neurotherapeutics       Date:  2017-01       Impact factor: 7.620

Review 10.  Use of functional magnetic resonance imaging in the early identification of Alzheimer's disease.

Authors:  Christina E Wierenga; Mark W Bondi
Journal:  Neuropsychol Rev       Date:  2007-05-03       Impact factor: 7.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.